Concepts (82)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetic Ketoacidosis | 2 | 2019 | 12 | 1.300 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2024 | 635 | 1.080 |
Why?
|
| Diabetes Mellitus | 2 | 2019 | 515 | 0.910 |
Why?
|
| Thrombocythemia, Essential | 1 | 2022 | 3 | 0.810 |
Why?
|
| Primary Myelofibrosis | 1 | 2022 | 10 | 0.800 |
Why?
|
| Hyperglycemia | 2 | 2020 | 98 | 0.770 |
Why?
|
| Diplopia | 1 | 2021 | 9 | 0.760 |
Why?
|
| Diabetic Neuropathies | 1 | 2021 | 8 | 0.760 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2024 | 657 | 0.690 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2022 | 167 | 0.670 |
Why?
|
| Hospitalization | 2 | 2024 | 1290 | 0.660 |
Why?
|
| Gastroparesis | 1 | 2019 | 8 | 0.650 |
Why?
|
| Ketosis | 1 | 2019 | 3 | 0.650 |
Why?
|
| Hypoparathyroidism | 1 | 2019 | 7 | 0.630 |
Why?
|
| Colorectal Surgery | 1 | 2019 | 53 | 0.610 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 42 | 0.600 |
Why?
|
| Metformin | 1 | 2019 | 63 | 0.600 |
Why?
|
| Autoantibodies | 1 | 2019 | 172 | 0.590 |
Why?
|
| Acute Kidney Injury | 1 | 2019 | 132 | 0.560 |
Why?
|
| Blood Glucose | 2 | 2020 | 461 | 0.550 |
Why?
|
| Autoimmune Diseases | 1 | 2019 | 220 | 0.550 |
Why?
|
| Emergency Service, Hospital | 1 | 2024 | 1021 | 0.530 |
Why?
|
| Insulin | 1 | 2018 | 674 | 0.470 |
Why?
|
| Argyria | 1 | 2013 | 1 | 0.430 |
Why?
|
| Silver Compounds | 1 | 2013 | 1 | 0.430 |
Why?
|
| Sella Turcica | 1 | 2013 | 1 | 0.430 |
Why?
|
| Dacarbazine | 1 | 2013 | 18 | 0.430 |
Why?
|
| Pituitary Neoplasms | 1 | 2013 | 21 | 0.420 |
Why?
|
| Sarcoma | 1 | 2013 | 37 | 0.420 |
Why?
|
| Complementary Therapies | 1 | 2013 | 56 | 0.410 |
Why?
|
| Glucagon | 1 | 2011 | 33 | 0.370 |
Why?
|
| Pheochromocytoma | 1 | 2011 | 24 | 0.360 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2011 | 40 | 0.360 |
Why?
|
| Agranulocytosis | 1 | 2010 | 6 | 0.350 |
Why?
|
| Methimazole | 1 | 2010 | 8 | 0.350 |
Why?
|
| Thyroid Crisis | 1 | 2010 | 5 | 0.350 |
Why?
|
| Plasmapheresis | 1 | 2010 | 18 | 0.350 |
Why?
|
| Antithyroid Agents | 1 | 2010 | 18 | 0.350 |
Why?
|
| Aged | 7 | 2024 | 13412 | 0.300 |
Why?
|
| Humans | 14 | 2024 | 59282 | 0.290 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 631 | 0.290 |
Why?
|
| Retrospective Studies | 4 | 2024 | 6071 | 0.210 |
Why?
|
| Hydroxyurea | 1 | 2022 | 19 | 0.200 |
Why?
|
| Female | 7 | 2024 | 30695 | 0.190 |
Why?
|
| Middle Aged | 5 | 2024 | 16310 | 0.180 |
Why?
|
| Prognosis | 2 | 2022 | 1599 | 0.170 |
Why?
|
| Male | 6 | 2024 | 27727 | 0.170 |
Why?
|
| 3-Hydroxybutyric Acid | 1 | 2019 | 2 | 0.160 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 1 | 2019 | 1 | 0.160 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2019 | 16 | 0.160 |
Why?
|
| Hypocalcemia | 1 | 2019 | 16 | 0.160 |
Why?
|
| Insulin Infusion Systems | 1 | 2018 | 10 | 0.160 |
Why?
|
| Cohort Studies | 1 | 2024 | 2372 | 0.150 |
Why?
|
| Glucocorticoids | 1 | 2020 | 179 | 0.150 |
Why?
|
| Coronary Angiography | 1 | 2019 | 176 | 0.150 |
Why?
|
| Thyroid Neoplasms | 1 | 2019 | 71 | 0.150 |
Why?
|
| Income | 1 | 2019 | 156 | 0.150 |
Why?
|
| Hypoglycemic Agents | 1 | 2018 | 192 | 0.130 |
Why?
|
| Contrast Media | 1 | 2019 | 408 | 0.130 |
Why?
|
| Thyroidectomy | 2 | 2019 | 31 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2018 | 605 | 0.110 |
Why?
|
| Algorithms | 1 | 2018 | 976 | 0.110 |
Why?
|
| Risk Assessment | 1 | 2020 | 1920 | 0.110 |
Why?
|
| Lung Neoplasms | 1 | 2019 | 582 | 0.100 |
Why?
|
| Gastrointestinal Motility | 1 | 2011 | 7 | 0.090 |
Why?
|
| Gastrointestinal Agents | 1 | 2011 | 25 | 0.090 |
Why?
|
| Colonoscopy | 1 | 2011 | 86 | 0.090 |
Why?
|
| Thyrotoxicosis | 1 | 2010 | 7 | 0.090 |
Why?
|
| Graves Disease | 1 | 2010 | 15 | 0.090 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 933 | 0.090 |
Why?
|
| Aged, 80 and over | 2 | 2019 | 5128 | 0.070 |
Why?
|
| Treatment Outcome | 1 | 2010 | 5283 | 0.040 |
Why?
|
| SEER Program | 1 | 2019 | 66 | 0.040 |
Why?
|
| Thyroid Gland | 1 | 2019 | 79 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 228 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 452 | 0.040 |
Why?
|
| United States | 2 | 2020 | 7385 | 0.030 |
Why?
|
| Incidence | 1 | 2020 | 1236 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2019 | 902 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 2337 | 0.030 |
Why?
|
| Adult | 1 | 2010 | 15663 | 0.030 |
Why?
|
| Risk Factors | 1 | 2020 | 4982 | 0.020 |
Why?
|